Protein biomarkers in breast cancer-derived extracellular vesicles for use in liquid biopsies

Li, Dan; Lai, Wenjia; Fan, Di; Fang, Qiaojun

doi:10.1152/ajpcell.00048.2021

Cited by 20 publications

(17 citation statements)

References 111 publications

(120 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of EVs as a liquid biopsy approach for the diagnosis, classification, and prognosis of BC attracted the interest of multiple groups [ 9 ]. In the literature, several EVs associated proteins have been suggested as possible specific markers for detecting EVs released by cancer cells [ 10 ]. For example, EDIL3 [ 11 ] and Claudin7 [ 12 ] have been presented as possible makers of early breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Fast quantification of extracellular vesicles levels in early breast cancer patients by Single Molecule Detection Array (SiMoA)

Morasso

Ricciardi

Sproviero

et al. 2021

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Preliminary reports suggest that extracellular vesicles (EVs) might be a promising biomarker for breast cancer (BC). However, the quantification of plasmatic levels of EVs is a complex task. To overcome these limitations, we developed a new, fast, and easy to use assay for the quantification of EVs directly in plasma based on the use of Single-Molecule Array (SiMoA). Methods By using SiMoA to identify CD9+/CD63+ EVs, we analyzed plasma samples of 181 subjects (95 BC and 86 healthy controls, HC). A calibration curve, made of a serial dilution of lyophilized standards from human plasma, was used in each run to ensure the obtainment of quantitative results from the assay. In a subgroup of patients, EVs concentrations were estimated in plasma before and after 30 days from cancer surgery. Additional information on the size of EVs were also acquired using a Nanosight system to obtain a clearer understanding of the mechanism underlying the releases of EVs associated with the presence of cancer. Results The measured levels of EVs resulted significantly higher in BC patients (median values 1179.1 ng/µl vs 613.0 ng/µl, p < 0.0001). ROC curve was used to define the optimal cut-off level of the test at 1034.5 ng/µl with an AUC of 0.75 [95% CI 0.68–0.82]. EVs plasmatic concentrations significantly decreased after cancer surgery compared to baseline values (p = 0.014). No correlation was found between EVs concentration and clinical features of BC. Conclusion SiMoA assay allows plasmatic EVs levels detection directly without any prior processing. EVs levels are significantly higher in BC patients and significantly decreases after cancer surgery.

show abstract

Section: Introductionmentioning

confidence: 99%

Fast quantification of extracellular vesicles levels in early breast cancer patients by Single Molecule Detection Array (SiMoA)

Morasso

Ricciardi

Sproviero

et al. 2021

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…As mentioned above, breast cancer types are divided into 4 major groups depending on clinical data and specific marker gene expression pattern [17][18][19][20][21][22][23][24][25][26]. Molecular types are usually diagnosed using the information about presence or absence of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu receptor expression and further prognosis and therapy strategies are based on this classification.…”

Section: Discussionmentioning

confidence: 99%

“…Every subtype is characterized by specific marker genes expression, and year to year, their number continues to increase. Intermediate * -percentage according to [17][18][19][20][21][22][23][24][25].…”

Section: Discussionmentioning

confidence: 99%

Tristetraproline in breast cancer: treat or trick?

Serhii

Anastasiia

Oksana

et al. 2022

Preprint

View full text Add to dashboard Cite

Breast cancer is one of the most common types of cancer. It is very heterogeneous, hence still complicated to diagnose despite of decades of research. Post-transcriptional regulation of gene expression is crucial for modulation of cell networking and is performed via different regulatory molecules. Tristetraproline (TTP) is RNA-binding protein which binds to AU-rich elements within its target mRNAs and negatively regulates multiple transcripts, including pro-inflammatory and pro-oncogenic. Its expression level correlates with patient outcomes in different types of cancer and is considered as a potential molecular marker. Here we examined TTPs expression level in different molecular subtypes of breast cancer. Our findings show that TTP expression is significantly higher in HER2-enriched breast cancer compared to other types and adjacent tissues. We also investigated changes in the TTPs methylation status under temozolomide and doxorubicin treatment in MCF-7 cell line and found that temozolomide decreased TTPs methylation, which can potentially improve patient prognosis. In contrast, another well-known anticancer agent, doxorubicin, promoted TTPs methylation, which may impair an expected therapeutic effect of this drug.

show abstract

“…The tumor-derived exosomes may promote tumor progression by modulating the host micro-environment in a distant site. Since the tumor-derived exosomes preferentially fuse with resident cells at their predicted destination, the tumor exosome integrins may determine organotropic metastases [ 258 ]. There is data indicating that there are protein markers within the extracellular vesicles derived from breast cancer cells [ 259 ].…”

Section: Combined Analysis Of Ctdna With Other Parametersmentioning

confidence: 99%

The Role of Cell-Free DNA in Cancer Treatment Decision Making

Telekes

Horváth

2022

Cancers

View full text Add to dashboard Cite

The aim of this review is to evaluate the present status of the use of cell-free DNA and its fraction of circulating tumor DNA (ctDNA) because this year July 2022, an ESMO guideline was published regarding the application of ctDNA in patient care. This review is for clinical oncologists to explain the concept, the terms used, the pros and cons of ctDNA; thus, the technical aspects of the different platforms are not reviewed in detail, but we try to help in navigating the current knowledge in liquid biopsy. Since the validated and adequately sensitive ctDNA assays have utility in identifying actionable mutations to direct targeted therapy, ctDNA may be used for this soon in routine clinical practice and in other different areas as well. The cfDNA fragments can be obtained by liquid biopsy and can be used for diagnosis, prognosis, and selecting among treatment options in cancer patients. A great proportion of cfDNA comes from normal cells of the body or from food uptake. Only a small part (<1%) of it is related to tumors, originating from primary tumors, metastatic sites, or circulating tumor cells (CTCs). Soon the data obtained from ctDNA may routinely be used for finding minimal residual disease, detecting relapse, and determining the sites of metastases. It might also be used for deciding appropriate therapy, and/or emerging resistance to the therapy and the data analysis of ctDNA may be combined with imaging or other markers. However, to achieve this goal, further clinical validations are inevitable. As a result, clinicians should be aware of the limitations of the assays. Of course, several open questions are still under research and because of it cfDNA and ctDNA testing are not part of routine care yet.

show abstract

Protein biomarkers in breast cancer-derived extracellular vesicles for use in liquid biopsies

Cited by 20 publications

References 111 publications

Fast quantification of extracellular vesicles levels in early breast cancer patients by Single Molecule Detection Array (SiMoA)

Fast quantification of extracellular vesicles levels in early breast cancer patients by Single Molecule Detection Array (SiMoA)

Tristetraproline in breast cancer: treat or trick?

The Role of Cell-Free DNA in Cancer Treatment Decision Making

Contact Info

Product

Resources

About